Neurocrine biosciences® presents ingrezza® (valbenazine) capsules interim data demonstrating sustained improvements in chorea associated with huntington's disease through week 50 at huntington study group 2023

San diego , nov. 2, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced interim results from the ongoing open-label kinect®-hd2 study about ingrezza® (valbenazine) capsules when used for the long-term treatment of adults with chorea associated with huntington's disease (hd). interim data suggest one-capsule, once-daily ingrezza improved chorea at the first evaluation at week 2 with sustained efficacy through week 50.
NBIX Ratings Summary
NBIX Quant Ranking